Reported about 19 hours ago
BridgeBio Pharma Inc. raised $300 million by partially monetizing its European royalty rights for BEYONTTRA, an oral treatment for transthyretin amyloidosis. The financing, arranged with HealthCare Royalty and Blue Owl Capital, provides upfront capital by giving away 60% of royalties on the first $500 million of annual sales in Europe. This deal aims to strengthen BridgeBio's financial position and support its ongoing projects, including the launch of Attruby in the US.
Source: YAHOO